血府逐瘀丸治疗结核性包裹性胸膜炎64例临床分析  

Clinical analysis of 64 cases with Xuefuzhuyu pills in the treatment of encapsulated tuberculous pleurisy

作　　者：李维芳 

机构地区：[1]辽宁省锦州市传染病医院,辽宁锦州121017

出　　处：《中国医药科学》2013年第17期122-123,127,共3页China Medicine And Pharmacy

摘　　要：目的探讨血府逐瘀丸治疗结核性包裹性胸膜炎的疗效。方法对64例结核性包裹性胸膜炎患者的治疗结果进行回顾性分析。结果64例患者中在常规抗结核治疗基础上加服血府逐瘀丸的32例患者，胸水平均吸收时间8—16周，无一例留有胸膜肥厚及粘连：单纯抗结核治疗的32例患者中16例胸水平均吸收时间在16周以内，其余16例患者均超过16周以上，其中无变化者3例。并且80％的患者均留有不同程度的胸膜肥厚及粘连。结论在标准、规律、强化抗结核治疗的前提下，应用血府逐瘀丸治疗结核性包裹性胸膜炎，具有明确的减轻胸膜肥厚、粘连、促进胸水吸收的特点。Objective To study the curative effect of Xuefuzhuyu pills in the treatment of encapsulated tuberculous pleurisy. Methods A retrospective analysis was performed on the results of the 64 patients with encapsulated tuberculous pleurisy. Results Based on routine antituberculous therapy, of the 64 patients, 32patients were plused Xuefuzhuyu pills, pleural effusion average absorption time was 8 - 16 weeks, and no patients were left pleural thickening and adhesion. Among the 32 patients in treatment of tuberculosis, 16 cases of hydrothorax average absorption time lasted within 16 weeks, while the other 16 patients were over 16 weeks, and there were no any changes in 3 cases. As a result, 80% of the patients had pleural thickening and adhesion in different degrees. Conclusion In the premise of standards, rules, strengthening anti-tuberculosis treatment, with the application of Xuefuzhuyu pills in the treatment of encapsulated tuberculous pleurisy, pleural thickening and adhesion was significantly reduced, and thus promoted the characteristics of pleural effusion absorption.

关 键 词：血府逐瘀丸 包裹性 结核性胸膜炎 胸膜肥厚粘连 

分 类 号：R521.7[医药卫生—内科学]